Gina D. Jefferson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gina D. Jefferson has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
Christopher Spankovich
Department of Otolaryngology – Head and Neck Surgery, University of Mississippi Medical Center, Jackson, MS, USA
3 shared publications- Charlotte S. Taylor
University of Mississippi Medical Center
2 shared publications Oishika Paul
Department of Otolaryngology – Head and Neck Surgery, University of Mississippi Medical Center, Jackson, MS, USA
2 shared publications- Alexander O. Johnson
University of Mississippi Medical Center, School of Medicine, 726 Sherwood Dr, Jackson, MS 39216, United States of America
1 shared publication Alexandra Rose
School of Medicine, University of Mississippi Medical Center, Jackson, MS, USA
1 shared publication- Anaïs Rameau
Weill Cornell Medical College
1 shared publication
Latest Publications
- Open Access
- 7 November 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (21) , 9990
Benzyl Isothiocyanate Pretreatment Enhances Chemoradiation Response in HPV-Negative Head and Neck Squamous Cell Carcinoma
Head and neck squamous cell carcinoma (HNSCC) accounts for ~3% of U.S. cancer diagnoses, and many patients present with locally or regionally advanced disease. Despite multimodal standard-of-care (SOC) treatment, the median overall survival for recurrent or metastatic disease remains ~12 months. Acquired resistance to cisplatin (CDDP) and radiotherapy (RT) remains a central barrier to durable response, motivating neoadjuvant strategies to improve efficacy in resistant tumors. Benzyl isothiocyanate (BITC) is a dietary phytochemical with selective anticancer activity. Across four patient-matched HNSCC cell lines spanning a range of intrinsic sensitivities to CDDP or RT, pretreatment with BITC before RT and CDDP significantly increased HNSCC cell death as measured by caspase-3/7 activity, regardless of each cell line’s single-agent sensitivity. Within 24 h, BITC elevated cytoplasmic ROS across all lines: BITC-resistant cell lines countered this with a more robust increase in the GSH/GSSG ratio and retained viability, whereas the BITC-sensitive lines mounted a weaker glutathione (GSH) response and required rescue with exogenous GSH or N-acetylcysteine (NAC), indicating redox-sensitive cytotoxicity. Transcriptomic time-course analysis suggested that BITC induces a coordinated stress response, including proteotoxic HSF1 activation, and suppresses DNA replication and homologous recombination repair, thereby supporting a transcriptional basis for the observed sensitization to DNA-damaging therapy. By enhancing the efficacy of RT and CDDP in HPV-negative HNSCC, BITC may be a promising neoadjuvant strategy to improve the therapeutic index of chemotherapy and radiation in these patients, warranting further investigation.
- 7 November 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (21) , 9990
Open AccessBenzyl Isothiocyanate Pretreatment Enhances Chemoradiation Response in HPV-Negative Head and Neck Squamous Cell Carcinoma
Head and neck squamous cell carcinoma (HNSCC) accounts for ~3% of U.S. cancer diagnoses, and many patients present with locally or regionally advanced disease. Despite multimodal standard-of-care (SOC) treatment, the median overall survival for recurrent or metastatic disease remains ~12 months. Acquired resistance to cisplatin (CDDP) and radiotherapy (RT) remains a central barrier to durable response, motivating neoadjuvant strategies to improve efficacy in resistant tumors. Benzyl isothiocyanate (BITC) is a dietary phytochemical with selective anticancer activity. Across four patient-matched HNSCC cell lines spanning a range of intrinsic sensitivities to CDDP or RT, pretreatment with BITC before RT and CDDP significantly increased HNSCC cell death as measured by caspase-3/7 activity, regardless of each cell line’s single-agent sensitivity. Within 24 h, BITC elevated cytoplasmic ROS across all lines: BITC-resistant cell lines countered this with a more robust increase in the GSH/GSSG ratio and retained viability, whereas the BITC-sensitive lines mounted a weaker glutathione (GSH) response and required rescue with exogenous GSH or N-acetylcysteine (NAC), indicating redox-sensitive cytotoxicity. Transcriptomic time-course analysis suggested that BITC induces a coordinated stress response, including proteotoxic HSF1 activation, and suppresses DNA replication and homologous recombination repair, thereby supporting a transcriptional basis for the observed sensitization to DNA-damaging therapy. By enhancing the efficacy of RT and CDDP in HPV-negative HNSCC, BITC may be a promising neoadjuvant strategy to improve the therapeutic index of chemotherapy and radiation in these patients, warranting further investigation.
- 14 May 2026
- Published by SAGE Publications in Annals of Otology, Rhinology & Laryngology
- Vol. 135 (10) , 752-759
Comparison of Adult Tracheostomy Outcomes Before and After Implementation of a Dedicated Tracheostomy Team
Objective: (A) Determine patient and institutional factors associated with increased length of stay (LOS) and complications of tracheostomy, (B) Develop data-driven quality improvement in tracheostomy care. Design: Mixed methods protocol used cross-sectional survey assessing institutional trends in tracheostomy-specific care. Retrospective chart review compared tracheostomy patient outcomes prior to and during implementation of a multidisciplinary tracheostomy care team and standardized guidelines. Participants: Patients undergoing tracheostomy from January 2019 to December 2021 at a tertiary hospital. Methods: Patient factors, procedure type and indication, tracheostomy tube size, management timeline, insurance, and disease severity using Acute Physiology and Chronic Health Evaluation II (APACHE II) score were analyzed for associations with LOS and adverse events. Multivariate analyses controlled for APACHE II score and payer source. LOS and complications were compared between patients before and during implementation of multidisciplinary tracheostomy care team and standardized guidelines. Results: Three-hundred and eighteen patients met criteria with a 21.7% complication rate, average LOS of 24 days (SD = 28.523), and median LOS post-tracheostomy of 14 days (IQR 7, 29). Departments without standardized protocols had greater LOS ( F [1,316] = 28.706, P < .001]) and complication odds (OR = 2.92, P = .015, 95% CI[1.231, 6.930]). Larger tracheostomy tube size was linked to increased LOS (β = .253, t (314) = 4.741, P < .001, 95% CI[4.137, 10.081]). Delays from ventilation discontinuation to cuffless tube exchange and decannulation correlated with increased LOS (β = .406, t (184) = 6.321, P < .001, 95% CI[.928, 1.771]); (β = .554, t (129) = 7.625, P < .001, 95% CI[1.008, 1.715]). When focusing on a single department, comparing 2019 patients to 2021 patients (pre- and post-guideline and care team), overall, LOS decreased from 33.08 to 30.83 days ( P = .586). When excluding patients discharged on a ventilator, the 2019 group had average LOS of 37.938 days versus 33.41 days in 2021 ( P = .344). Conclusions: Standardized tracheostomy care guidelines and multidisciplinary care teams are critical to improving institutional outcomes. Data-driven approaches to quality improvement ensure efficient and targeted methods to improving patient care. Level of Evidence: 4
- 14 May 2026
- Published by SAGE Publications in Annals of Otology, Rhinology & Laryngology
- Vol. 135 (10) , 752-759
Comparison of Adult Tracheostomy Outcomes Before and After Implementation of a Dedicated Tracheostomy Team
Objective: (A) Determine patient and institutional factors associated with increased length of stay (LOS) and complications of tracheostomy, (B) Develop data-driven quality improvement in tracheostomy care. Design: Mixed methods protocol used cross-sectional survey assessing institutional trends in tracheostomy-specific care. Retrospective chart review compared tracheostomy patient outcomes prior to and during implementation of a multidisciplinary tracheostomy care team and standardized guidelines. Participants: Patients undergoing tracheostomy from January 2019 to December 2021 at a tertiary hospital. Methods: Patient factors, procedure type and indication, tracheostomy tube size, management timeline, insurance, and disease severity using Acute Physiology and Chronic Health Evaluation II (APACHE II) score were analyzed for associations with LOS and adverse events. Multivariate analyses controlled for APACHE II score and payer source. LOS and complications were compared between patients before and during implementation of multidisciplinary tracheostomy care team and standardized guidelines. Results: Three-hundred and eighteen patients met criteria with a 21.7% complication rate, average LOS of 24 days (SD = 28.523), and median LOS post-tracheostomy of 14 days (IQR 7, 29). Departments without standardized protocols had greater LOS ( F [1,316] = 28.706, P < .001]) and complication odds (OR = 2.92, P = .015, 95% CI[1.231, 6.930]). Larger tracheostomy tube size was linked to increased LOS (β = .253, t (314) = 4.741, P < .001, 95% CI[4.137, 10.081]). Delays from ventilation discontinuation to cuffless tube exchange and decannulation correlated with increased LOS (β = .406, t (184) = 6.321, P < .001, 95% CI[.928, 1.771]); (β = .554, t (129) = 7.625, P < .001, 95% CI[1.008, 1.715]). When focusing on a single department, comparing 2019 patients to 2021 patients (pre- and post-guideline and care team), overall, LOS decreased from 33.08 to 30.83 days ( P = .586). When excluding patients discharged on a ventilator, the 2019 group had average LOS of 37.938 days versus 33.41 days in 2021 ( P = .344). Conclusions: Standardized tracheostomy care guidelines and multidisciplinary care teams are critical to improving institutional outcomes. Data-driven approaches to quality improvement ensure efficient and targeted methods to improving patient care. Level of Evidence: 4
- Open Access
- 4 October 2024
- Published by Elsevier in Oral Oncology Reports
- Vol. 12
Validation of clinical tumor depth of invasion measure in patients with oral cavity cancer
- 4 October 2024
- Published by Elsevier in Oral Oncology Reports
- Vol. 12
Open AccessValidation of clinical tumor depth of invasion measure in patients with oral cavity cancer
- 17 July 2023
- Published by Springer Nature in Current Otorhinolaryngology Reports
- Vol. 11 (3) , 215-220
Reshaping Otolaryngology Through Workforce Heterogeneity
- 17 July 2023
- Published by Springer Nature in Current Otorhinolaryngology Reports
- Vol. 11 (3) , 215-220
Reshaping Otolaryngology Through Workforce Heterogeneity
- 4 July 2023
- Published by Springer Nature in Current Otorhinolaryngology Reports
- Vol. 11 (3) , 201-214
Allyship to Advance Diversity, Equity, and Inclusion in Otolaryngology: What We Can All Do
Purpose of review To summarize the current literature on allyship, providing a historical perspective, concept analysis, and practical steps to advance equity, diversity, and inclusion. This review also provides evidence-based tools to foster allyship and identifies potential pitfalls. Recent findings Allies in healthcare advocate for inclusive and equitable practices that benefit patients, coworkers, and learners. Allyship requires working in solidarity with individuals from underrepresented or historically marginalized groups to promote a sense of belonging and opportunity. New technologies present possibilities and perils in paving the pathway to diversity. Summary Unlocking the power of allyship requires that allies confront unconscious biases, engage in self-reflection, and act as effective partners. Using an allyship toolbox, allies can foster psychological safety in personal and professional spaces while avoiding missteps. Allyship incorporates goals, metrics, and transparent data reporting to promote accountability and to sustain improvements. Implementing these allyship strategies in solidarity holds promise for increasing diversity and inclusion in the specialty.
- 4 July 2023
- Published by Springer Nature in Current Otorhinolaryngology Reports
- Vol. 11 (3) , 201-214
Allyship to Advance Diversity, Equity, and Inclusion in Otolaryngology: What We Can All Do
Purpose of review To summarize the current literature on allyship, providing a historical perspective, concept analysis, and practical steps to advance equity, diversity, and inclusion. This review also provides evidence-based tools to foster allyship and identifies potential pitfalls. Recent findings Allies in healthcare advocate for inclusive and equitable practices that benefit patients, coworkers, and learners. Allyship requires working in solidarity with individuals from underrepresented or historically marginalized groups to promote a sense of belonging and opportunity. New technologies present possibilities and perils in paving the pathway to diversity. Summary Unlocking the power of allyship requires that allies confront unconscious biases, engage in self-reflection, and act as effective partners. Using an allyship toolbox, allies can foster psychological safety in personal and professional spaces while avoiding missteps. Allyship incorporates goals, metrics, and transparent data reporting to promote accountability and to sustain improvements. Implementing these allyship strategies in solidarity holds promise for increasing diversity and inclusion in the specialty.
- 7 April 2023
- Published by Elsevier in Otolaryngologic Clinics of North America
- Vol. 56 (2) , XIX-XX
Larynx Cancer
- 7 April 2023
- Published by Elsevier in Otolaryngologic Clinics of North America
- Vol. 56 (2) , XIX-XX
Larynx Cancer
- Top Cited Papers
- 25 March 2023
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 168 (4) , 571-592
Expert Consensus Statement: Management of Dysphagia in Head and Neck Cancer Patients
Objective: To develop an expert consensus statement (ECS) on the management of dysphagia in head and neck cancer (HNC) patients to address controversies and offer opportunities for quality improvement. Dysphagia in HNC was defined as swallowing impairment in patients with cancers of the nasal cavity, paranasal sinuses, nasopharynx, oral cavity, oropharynx, larynx, or hypopharynx.Methods: Development group members with expertise in dysphagia followed established guidelines for developing ECS. A professional search strategist systematically reviewed the literature, and the best available evidence was used to compose consensus statements targeted at providers managing dysphagia in adult HNC populations. The development group prioritized topics where there was significant practice variation and topics that would improve the quality of HNC patient care if consensus were possible.Results: The development group identified 60 candidate consensus statements, based on 75 initial proposed topics and questions, that focused on addressing the following high yield topics: (1) risk factors, (2) screening, (3) evaluation, (4) prevention, (5) interventions, and (6) surveillance. After 2 iterations of the Delphi survey and the removal of duplicative statements, 48 statements met the standardized definition for consensus; 12 statements were designated as no consensus.Conclusion: Expert consensus was achieved for 48 statements pertaining to risk factors, screening, evaluation, prevention, intervention, and surveillance for dysphagia in HNC patients. Clinicians can use these statements to improve quality of care, inform policy and protocols, and appreciate areas where there is no consensus. Future research, ideally randomized controlled trials, is warranted to address additional controversies related to dysphagia in HNC patients.
- 25 March 2023
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 168 (4) , 571-592
Top Cited PapersExpert Consensus Statement: Management of Dysphagia in Head and Neck Cancer Patients
Objective: To develop an expert consensus statement (ECS) on the management of dysphagia in head and neck cancer (HNC) patients to address controversies and offer opportunities for quality improvement. Dysphagia in HNC was defined as swallowing impairment in patients with cancers of the nasal cavity, paranasal sinuses, nasopharynx, oral cavity, oropharynx, larynx, or hypopharynx.Methods: Development group members with expertise in dysphagia followed established guidelines for developing ECS. A professional search strategist systematically reviewed the literature, and the best available evidence was used to compose consensus statements targeted at providers managing dysphagia in adult HNC populations. The development group prioritized topics where there was significant practice variation and topics that would improve the quality of HNC patient care if consensus were possible.Results: The development group identified 60 candidate consensus statements, based on 75 initial proposed topics and questions, that focused on addressing the following high yield topics: (1) risk factors, (2) screening, (3) evaluation, (4) prevention, (5) interventions, and (6) surveillance. After 2 iterations of the Delphi survey and the removal of duplicative statements, 48 statements met the standardized definition for consensus; 12 statements were designated as no consensus.Conclusion: Expert consensus was achieved for 48 statements pertaining to risk factors, screening, evaluation, prevention, intervention, and surveillance for dysphagia in HNC patients. Clinicians can use these statements to improve quality of care, inform policy and protocols, and appreciate areas where there is no consensus. Future research, ideally randomized controlled trials, is warranted to address additional controversies related to dysphagia in HNC patients.
- Open Access
- 24 September 2022
- Published by Elsevier in Radiology Case Reports
- Vol. 17 (12) , 4459-4461
A case of head and neck cutaneous squamous cell carcinoma highlighting aggressive perineural features
- 24 September 2022
- Published by Elsevier in Radiology Case Reports
- Vol. 17 (12) , 4459-4461
Open AccessA case of head and neck cutaneous squamous cell carcinoma highlighting aggressive perineural features
- 1 November 2021
- Published by Elsevier in American Journal of Otolaryngology
- Vol. 42 (6) , 103110
An interesting case of metastatic papillary thyroid carcinoma to the face
- 1 November 2021
- Published by Elsevier in American Journal of Otolaryngology
- Vol. 42 (6) , 103110
An interesting case of metastatic papillary thyroid carcinoma to the face
- 1 October 2021
- Published by Elsevier in Cancer Epidemiology
- Vol. 74, 102011
Head and neck squamous cell carcinomas among males of the three largest Asian diasporas in the US, 2004–2013
- 1 October 2021
- Published by Elsevier in Cancer Epidemiology
- Vol. 74, 102011
Head and neck squamous cell carcinomas among males of the three largest Asian diasporas in the US, 2004–2013